Skip to content
TrialScanner

NCT02822495

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No phase registeredNo longer availableATRALead

Registry record

Lead sponsor
Atara Biotherapeutics
Conditions
Epstein-Barr Virus (EBV) Infections; Lymphoproliferative Disorders; EBV+ Associated Lymphoma; EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Epstein-Barr Viremia
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02822495 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.